Tissue-agnostic drug development approaches have their own set of scientific and financial considerations, but some drugmakers are taking on those challenges.
The approval of two molecularly targeted, tissue-agnostic therapies, has shown researchers that there is a path forward for other pan-cancer markers.
Flye and wtdbg2, both released this year, work with Pacific Biosciences and Oxford Nanopore data and can assemble bacterial and more complex genomes.
The study researchers further reported that high matching scores predicted both better progression-free and overall survival.
While the study didn't meet its primary endpoint, it showed the potential of transcriptomics to match cancer patients to beneficial treatments.
The researchers said a microbiome-based test could expand the number of individuals who are screened for the disease.
Analyzing mutational signatures in cancer cell lines and xenografts, investigators identified mutagenic processes that do or don't remain active in vitro.
Some 43 percent of new mothers and 23 percent of new fathers leave full-time employment in STEM in the years after having a child, Science Careers says.
Based on gene expression, researchers identified cell clusters in testes samples from two adult men and two infants, providing clues that may eventually aid fertility treatments.
In PNAS this week: sepsis-related copy number changes, three-dimensional leaf transcriptomes of plants grow in dark or in light-dark cycles, and more.
The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.
Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.
In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.